Ratings ONCS BRAS

Equities

Market Closed - Sao Paulo Other stock markets 04:07:54 2024-06-06 pm EDT			5-day change	1st Jan Change
7.23 ^BRL	-0.96%		-19.22%	-44.38%

May. 22	Oncoclínicas do Brasil Serviços Médicos S.A. announced that it expects to receive BRL 1.5002 billion in funding	CI
May. 14	Oncoclínicas do Brasil Serviços Médicos S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's profit outlook over the next few years is a strong asset.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

The company is in debt and has limited leeway for investment
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality